Phase 3 Macular Degeneration Clinical Trials
15 recruitingPhase 3
What is a Phase 3 trial?
Phase 3 trials compare the new treatment against the current standard of care in large groups, often hundreds to thousands of participants. Successful Phase 3 results are typically required for regulatory approval.
Showing 1–15 of 15 trials
Recruiting
Phase 3
A Study of the Efficacy, Safety, and Pharmacokinetics (PK) of the Port Delivery System With Ranibizumab (PDS) in Chinese Participants With Neovascular Age-related Macular Degeneration (nAMD)
Neovascular Age-related Macular DegenerationnAMD
Hoffmann-La Roche68 enrolled16 locationsNCT05562947
Recruiting
Phase 3
Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-related Macular Degeneration (AQUARIUS)
Neovascular Age-Related Macular Degeneration (nAMD)Wet AMD
Adverum Biotechnologies, Inc.284 enrolled36 locationsNCT07482176
Recruiting
Phase 3
A Study of 36-Week Refill Exchanges of Port Delivery System (PDS) With Ranibizumab in nAMD
Neovascular Age-related Macular Degeneration
Hoffmann-La Roche250 enrolled56 locationsNCT06847542
Recruiting
Phase 2Phase 3
A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002)
Age-Related Macular DegenerationMacular DegenerationChoroidal Neovascularization+1 more
EyeBiotech Ltd.960 enrolled20 locationsNCT07440225
Recruiting
Phase 3
Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration
Neovascular Age-Related Macular Degeneration (nAMD)
4D Molecular Therapeutics480 enrolled94 locationsNCT07064759
Recruiting
Phase 3
Study to Assess the Injection Burden, Adverse Events, Change in Disease Activity, and Long-Term Preservation of Visual Acuity of Surabgene Lomparvovec in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD)
Neovascular Age-related Macular Degeneration
AbbVie561 enrolled100 locationsNCT07007065
Recruiting
Phase 3
Efficacy and Safety of LX102 Gene Therapy in Patients With Neovascular Age-related Macular Degeneration (nAMD) (STELLAR)
Neovascular Age-Related Macular Degeneration (nAMD)Wet AMD
Innostellar Biotherapeutics Co.,Ltd332 enrolled31 locationsNCT07317934
Recruiting
Phase 3
Vitrectomy, Subretinal Tissue Plasminogen Activator (TPA) and Intravitreal Gas for Submacular Haemorrhage Secondary to Exudative (Wet) Age-related Macular Degeneration (TIGER).
Eye DiseasesMacular Degeneration, WetSub-Macular Hemorrhage
King's College Hospital NHS Trust210 enrolled36 locationsNCT04663750
Recruiting
Phase 3
Home OCT-Guided Treatment Versus Treat and Extend for the Management of Neovascular AMD
Neovascular Age-related Macular Degeneration
Jaeb Center for Health Research600 enrolled64 locationsNCT05904028
Recruiting
Phase 3
Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-Related Macular Degeneration
Neovascular Age-Related Macular Degeneration (nAMD)Wet AMD
Adverum Biotechnologies, Inc.284 enrolled79 locationsNCT06856577
Recruiting
Phase 3
QA108 Phase III Study in Subjects With Intermediate AMD
Intermediate Age-Related Macular Degeneration
Smilebiotek Zhuhai Limited400 enrolled1 locationNCT07189169
Recruiting
Phase 3
A Efficacy and Safety Study of Ranibizumab 10mg/ml Injection (Incepta) in Patients With Diabetic Macular Edema
Retinal DegenerationMacular DegenerationDiabetic Retinopathy+3 more
Incepta Pharmaceuticals Ltd70 enrolled1 locationNCT06305416
Completed
Phase 3Phase 4
Intravitreal dexamethasone for resistant wet-AMD
Wet aged macular degenerationResistent choroidal neovascularization
A.O.U. Sassari20 enrolled1 locationACTRN12618001102268
Recruiting
Phase 3
The RAAMP study. Ranibizumab versus aflibercept for age-related macular degeneration, using multifocal objective pupil perimetry.
wet age related macular degeneration (AMD)
Australian National University (ANU)60 enrolled2 locationsACTRN12614000497606
Not Yet Recruiting
Phase 3Phase 4
To investigate the role of Intravitreal Aflibercept (Eylea) in the treatment of patients whose wet Age related Macular degeneration is not adequately controlled with conventional anti VEGF (intravitreal Avastin or Lucentis) treatment.
Exudative (Wet) Age related Macular Degeneration
Greenlane Clinical Centre Auckland District Health Board50 enrolled1 locationACTRN12613001020774